Posting of Annual Report and Notice of AGM

RNS Number : 6468Z

Medica Group PLC

25 May 2021

 

25 May 2021

Medica Group Plc

Posting of Annual Report, Accounts, and Notice of AGM

Update on dividend payment date

Medica Group Plc (LSE:MGP), the UK and Ireland market leader in the provision of teleradiology services, today announces that the Company's annual report and accounts (Annual Report) for the year ended 31 December 2020, and the notice of the Company's annual general meeting (AGM) have been posted to those shareholders who have opted out of receiving electronic communications.

Electronic copies of these documents are available on the Company's website at

www.medicagroupplc.com/investors/results-and-reports

A copy of the Annual Report and Financial Statements will today be submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism  

The AGM will be held on 16 June 2021 at 10.30am. Consistent with current public safety measures, shareholders will not be able to attend the meeting in person. However, the Company has made arrangements for shareholders to attend the meeting remotely. There will be a live webcast of the meeting and shareholders will be able to submit questions electronically. To participate, shareholders will need to register to attend the meeting by visiting the AGM section of our website at: www.medicagroupplc.com/investors/agm . Shareholders may also submit questions in advance of the meeting by email to [e-mail] .

All valid proxy votes will be included in the poll to be taken on each resolution at the meeting.

Shareholders are urged to register their proxy appointment electronically via Medica Group's Registrar's website at  www.signalshares.com   by 10.00am on 14 June 2021.

Dividend update

The company would also like to provide clarification on detail issued in the announcement dated 11 May 2021, "Results for the year ended 31 December 2020", which incorrectly stated that the final dividend will be paid on 23 July 2021 to shareholders on the register as at 24 June 2021. Subject to shareholder approval at the AGM, the final dividend will be paid on 23 July 2021 to shareholders on the register as at 25 June 2021.  

For further information, please contact:  

Medica Group Plc: Roy Davis, Chairman	[phone]
Investec Bank plc (Joint Broker) Sara Hale Daniel Adams Virginia Bull	[phone]
Liberum (Joint Broker) Bidhi Bhoma Richard Lindley	[phone]
FTI Consulting Victoria Foster Mitchell Sam Purewal	[phone]

About Medica Group PLC

Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.

Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition, Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.

The Company currently offers two primary services to hospital radiology departments:

· NightHawk - urgent reporting service

· Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.

These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.

Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.

For more information please visit: www.medicagroupplc.com  

 

END

 

 

NOAPPUQCAUPGGQC